Kalaris Therapeutics logo
Kalaris Therapeutics
KLRS | NASDAQ
Chart Builder DCF Calculator
$1.46
-$0.11 (-7.30%)
At close: Nov 16, 2026, 4:00 PM ET
$1.46
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Kalaris Therapeutics Company Profile

Company profile explained

Company Profile

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.

Key Executives

Name Position
Andrew Oxtoby President, Chief Executive Officer & Director
Liisa Ann Bayko Chief Financial Officer & Treasurer
Amy Vandekop Interim Principal Accounting Officer & Corporate Controller
Jill E. Porter Senior Vice President of CMC
Kristine Curtiss Senior Vice President of Clinical
Matthew Feinsod Chief Medical Officer
Michael Philip Dybbs Director & Co-Founder
Napoleone Ferrara Independent Director & Co-Founder
Srinivas Akkaraju Director & Co-Founder

Latest SEC Filings

Date Type Title
Oct 26, 2026 SC 13G Statement of acquisition of beneficial ownership b...
View All SEC Filings ➞
Kalaris Therapeutics
Kalaris Therapeutics logo
Country United States
IPO Date Jul 30, 2020
Industry Biotechnology
Sector Healthcare
Employees 20
CEO Andrew Oxtoby

Contact Details

400 Connell Drive Berkeley Heights, New Jersey 07922 United States

Stock Details

Ticker Symbol KLRS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001754068
CUSIP Number 482929106
ISIN Number US4829291065
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.